Immunoglobulin E specific for Sorghum halepense pollen allergens (IgE (S. halepense))

Human Immunoglobulin E (IgE) antibodies specific for Sorghum halepense (Johnson grass) pollen allergens are the primary mediators of allergic sensitization and clinical symptoms in individuals with Johnson grass allergy. These antibodies recognize specific proteins within the pollen, most notably the major allergen Sor h 1 (a beta-expansin) and Sor h 7 (a polocalcin) [1][4]. Once produced by plasma cells, these allergen-specific IgE molecules circulate and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to Sorghum halepense pollen, the allergens cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes, which lead to symptoms of allergic rhinitis and asthma [2]. Therapeutic strategies targeting these antibodies, such as the monoclonal antibody Omalizumab, aim to sequester free IgE and prevent its interaction with receptors, thereby reducing the allergic inflammatory cascade [3]. Monitoring levels of these specific IgE antibodies is a standard diagnostic tool for identifying sensitivity and assessing the efficacy of allergen-specific immunotherapy [4]. Sources: [1] WHO/IUIS Allergen Nomenclature Sub-Committee. Sorghum halepense. http://www.allergen.org/viewallergen.php?aid=721 [2] Gould HJ, Sutton BJ. IgE in allergy and asthma. Nature. 2008;454(7203):445-454. [3] Xolair (omalizumab) [Prescribing Information]. Genentech, Inc.; 2023. [4] Sharma S, et al. Molecular and immunological characterization of Sor h 1, the major allergen of Johnson grass pollen. Mol Immunol. 2015;66(2):211-220. [5] Maurer M, et al. Ligelizumab for Chronic Spontaneous Urticaria. N Engl J Med. 2019;381(14):1321-1332.

Other names

Johnson grass pollen-specific IgEAnti-Sorghum halepense IgEAnti-Sor h IgESorghum halepense-specific IgEHuman IgE specific for Johnson grass

Binding to the Cε3 domain of circulating IgE to prevent interaction with high-affinity FcεRI and low-affinity FcεRII (CD23) receptors [2][3]